Clinical trials: BCC - Basal Cell Carcinoma
Field Actinic Keratoses, Basal Cell Carcinoma
Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease
The aim of this study is to provide this investigational drug to patients who cannot be optimally treated with conventional therapies and to collect efficacy and safety data on the use of Metvix PDT in subjects with field actinic…
- Conditions
- Field Actinic Keratoses, Basal Cell Carcinoma, Bowen's Disease
- Trial name
- NCT00535080
- Testing
- Metvix (methyl aminolevulinate)
- Sponsor
- Galderma R&D
Recurrent Basal Cell Carcinoma
A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
This is a multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with non-Gorlin HF-BCC…
- Trial name
- NCT04155190
- Testing
- Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
- Where
- 14 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Basal Cell Carcinoma
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
The purpose of this study is to evaluate the long-term sustained clearance rate of superficial basal cell carcinoma during a 5 year period following treatment with imiquimod
- Trial name
- NCT00189241
- Testing
- imiquimod
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Vitiligo, Melanoma (Skin)
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
This study examines melanoma and nonmelanoma skin cancer in people diagnosed with vitiligo compared to matched controls.
- Conditions
- Vitiligo, Melanoma (Skin), Nonmelanoma Skin Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04969419
- Testing
- Exposure of skin cancer of interest
- Where
- United Kingdom
- Volunteers
- 75,771 people
- Sponsor
- Momentum Data
Basal Cell Carcinoma
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC).
- Trial name
- NCT04669808
- Testing
- STP705
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sirnaomics
Basal Cell Carcinoma
STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma.
- Trial name
- NCT01367665
- Testing
- vismodegib
- Where
- 181 sites in Argentina, Australia and 35 more
- Volunteers
- 1,232 people
- Sponsor
- Hoffmann-La Roche
Nodular Basal Cell Carcinoma
Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma
The primary objective is the observation and description of the preliminary efficacy of resiquimod gel 0.06% on a single nodular basal cell carcinoma (nBCC) in a small group of patients.
- Trial name
- NCT01808950
- Testing
- 0.06% Resiquimod Gel - A, 0.06% Resiquimod Gel - B, 0.06% Resiquimod Gel - C
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 4 people
- Sponsor
- Spirig Pharma Ltd.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Basal Cell Carcinoma
Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
Photodynamic therapy (PDT) was the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulated more photosensitiser than normal cells.
- Trial name
- NCT00472108
- Testing
- Photodynamic Therapy (PDT), Metvix cream
- Where
- 9 sites in United States
- Volunteers
- 65 people
- Sponsor
- Galderma R&D
Basal Cell Carcinoma, Skin Cancer
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of VP-315 when…
- Conditions
- Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin
- Trial name
- NCT05188729
- Testing
- Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose
- Where
- 13 sites in United States
- Volunteers
- 92 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.